Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* History of COPD for at least 12 months prior to baseline visit and chronic productive cough for 3 months in each of the 2 years prior to baseline visit~* FEV1/FVC ratio (post-bronchodilator) ≤ 70%~* FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted~* Treated with tiotropium for at least 3 months before enrollment~* At least 28 puffs of rescue medication during last week prior to randomization~Main Exclusion Criteria:~* COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled
- Placebo (Type: PLACEBO_COMPARATOR): Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled

Based on this trial design, predict the completion outcome and termination type (if applicable).